1）Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol 2009; 44(6): 518–34. 2）Yang X, Li Y, Sun Y, Zhang M, Guo C, Mirza IA, et al. Vonoprazan: a novel and potent alternative in the treatment of acid-related diseases. Dig Dis Sci 2018; 63(2): 302–11. 3）Sugimoto K, Uno T, Yamazaki H, Tateishi T. Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol 2008; 65(3): 437–9.4）Kagami T, Sahara S, Ichikawa H, Uotani T, Yamade M, Sugimoto M, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther 2016; 43(10): 1048–59. 5）Akiyama J, Hosaka H, Kuribayashi S, Moriyasu S, Hisada Y, Okubo H, et al. Efficacy of vonoprazan, a novel potassium-competitive acid blocker, in patients with proton pump inhibitor-refractory acid reflux. Digestion 2020; 101(2): 174–83. 6）Kawami N, Hoshino S, Hoshikawa Y, Takenouchi N, Umezawa M, Hanada Y, et al. Pathogenesis of potassium-competitive acid blocker-resistant non-erosive reflux disease. Digestion 2018; 98(3): 194–200. 9）Yadlapati R, Kahrilas PJ, Fox MR, Bredenoord AJ, Prakash Gyawali C, Roman S, et al. Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0©. Neurogastroenterol Motil 2021; 33(1): e14058. 7）Hamada S, Ihara E, Ikeda H, Muta K, Ogino H, Chinen T, et al. Clinical characterization of vonoprazan-refractory gastroesophageal reflux disease. Digestion 2021; 102(2): 197–204. 8）Iwakiri K, Fujiwara Y, Manabe N, Ihara E, Kuribayashi S, Akiyama J, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol 2022; 57(4): 267–85. 10）Kuribayashi S, Iwakiri K, Kawada A, Kawami N, Hoshino S, Takenouchi N, et al. Variant parameter values-as defined by the Chicago Criteria-produced by ManoScan and a new system with Unisensor catheter. Neurogastroenterol Motil 2015; 27(2): 188–94. 11）Kuribayashi S, Iwakiri K, Shinozaki T, Hosaka H, Kawada A, Kawami N, et al. Clinical impact of different cut-off values in high-resolution manometry systems on diagnosing esophageal motility disorders. J Gastroenterol 2019; 54(12): 1078–82. 12）Masuda T, Yano F, Omura N, Tsuboi K, Hoshino M, Yamamoto S, et al. Optimal cutoff value of integrated relaxation pressure on the esophagogastric junction to detect outflow obstruction using starlet high-resolution manometry system. J Gastroenterol 2021; 56(3): 231–9. 13）Ward BW, Wu WC, Richter JE, Lui KW, Castell DO. Ambulatory 24-hour esophageal pH monitoring. Technology searching for a clinical application. J Clin Gastroenterol 1986; 8 Suppl 1: 59–67. 14）Breumelhof R, Smout AJ. The symptom sensitivity index: a valuable additional parameter in 24-hour esophageal pH recording. Am J Gastroenterol 1991; 86(2): 160–4. 15）Weusten BL, Roelofs JM, Akkermans LM, Van Berge-Henegouwen GP, Smout AJ. The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data. Gastroenterology 1994; 107(6): 1741–5. 16）増田隆洋、矢野文章、秋元俊亮、坪井一人、小村伸朗、衛藤謙. なかなか学べない良性上部消化管疾患の低侵襲手術 2.GERD・食道裂孔ヘルニアに対する腹腔鏡下手術. 消化器外科 2022; (1): 25–36. 東京へるす出版.17）Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 2016; 43(2): 240–51.141文 献
元のページ ../index.html#155